Behavioral/Drug Therapy for Alcohol-Nicotine Dependence (Naltrexone/Nicotine Patch)
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Nov 2, 1999
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Meets criteria for alcohol and nicotine dependence.
- • Individuals will be outpatients with alcohol and nicotine dependence who have completed detoxification (medicated or nonmedicated) within the past 48-120 hours.
- • Smoking no less than 10 cigarettes/day and no greater than 50 cigarettes/day.
- • Motivated to quit smoking.
- • Willing and able to participate in the 12 week outpatient treatment.
- • Acceptable health.
- • Able to provide a collateral informant.
- • Willing to be followed for 6 months after treatment ends.
- • Willing and able to provide the names of three family members or friends to aid in locating participants for follow-up.
- Exclusion Criteria:
- • Current diagnosis of dependence on other substances except nicotine and alcohol.
- • Having moderately severe or severe alcohol withdrawal symptoms.
- • Recent (less than 48 hours) evidence of hazardous drinking (more than 2 drinks/day for females; 3 drinks/day for males).
- • History of opioid abuse.
- • Recent use of cocaine.
- • Not desiring to quit smoking.
- • Recent past or current pharmacotherapy involving naltrexone or transdermal nicotine systems.
- • History of psychosis.
- • Current suicidality, homicidally or psychiatric symptoms requiring other medications.
- • Presence of medical abnormalities that contraindicate naltrexone or nicotine replacement therapy.
- • Current treatment with psychotropic medications.
- • Pregnancy or nursing for female patients. Inability or unwillingness to participate in the 12-week outpatient treatment.
About The University Of Texas Health Science Center, Houston
The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Joy Schmitz
Principal Investigator
The University of Texas Health Science Center, Houston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials